Skip to main content

Table 4 Topics of CMR studies that used GBCAs in peer reviewed publications

From: Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to united states food and drug administration (FDA) guidelines

 

2004

2005

2006

2007

2008

2009

2010

Total

Myocardial infarction

6 (27.2)

3 (15.8)

9 (34.6)

5 (16.1)

5 (12.5)

17 (3.7)

16 (32)

61 (26.1)

Others cardiomyopathies*

1 (4.6)

6 (31.5)

4 (15.4)

10 (32.2)

11 (27.5)

10 (22.3)

10 (20)

52 (22.3)

Ischemia

6 (27.2)

2 (10.5)

5 (19.2)

3 (9.6)

7 (17.5)

5 (11.2)

6 (12)

34 (14.5)

Myocardial viability

5 (22.7)

3 (15.8)

2 (7.6)

1 (3.3)

6 (15)

4 (8.9)

6 (12)

27 (11.6)

Hypertrophic Cardiomyopathy

2 (9.1)

4 (21.1)

1 (3.9)

2 (6.5)

5 (12.5)

3 (6.6)

7 (14)

24 (10.3)

Myocarditis

1 (4.6)

0 (0)

0 (0)

1 (3.3)

0 (0)

0 (0)

0 (0)

2 (1.0)

Pulmonary Hypertension

1 (4.6)

1 (5.3)

0 (0)

1 (3.3)

0 (0)

2 (4.3)

0 (0)

5 (2.1)

Valvular disease

0 (0)

0 (0)

2 (7.7)

0 (0)

1 (2.5)

1 (2.3)

1 (2)

5 (2.1)

Cardiac mass

0 (0)

0 (0)

1 (3.9)

3 (9.6)

1 (2.5)

0 (0)

0 (0)

5 (2.1)

Others

0 (0)

0 (0)

2 (7.7)

5 (16.1)

4 (10)

3 (6.7)

4 (8)

18 (7.9)

Total

22 (100)

19 (100)

26 (100)

31 (100)

40 (100)

45 (100)

50 (100)

233 (100)

  1. Data is presented as number and percentages. * Heart Failure, Post-Surgery status, Deposit disease, ARVD, Atrial Fibrilation, Congenital Heart disease, Tokotsubo